Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3766672 | 0.99 | TACR2 (0.43) | TACR2TACR1 | |
| SCHEMBL493745 | 0.94 | TACR2 (0.43) | TACR2TACR1 | |
| SCHEMBL3761709 | 0.93 | TACR2 (0.45) | TACR2TACR1 | |
| SCHEMBL493759 | 0.92 | TACR2 (0.49) | TACR2TACR1 | |
| Hydrochloric Acid SCHEMBL3773045 | 0.92 | TACR2 (0.44) | TACR2TACR1 | |
| SCHEMBL3764734 | 0.92 | TACR2 (0.45) | TACR2TACR1 | |
| SCHEMBL5028804 | 0.92 | TACR2 (0.45) | TACR2TACR1 | |
| SCHEMBL3771236 | 0.90 | TACR2 (0.44) | TACR2TACR1 | |
| SCHEMBL3766893 | 0.90 | TACR2 (0.44) | TACR2TACR1 | |
| Hydrochloric Acid SCHEMBL3776356 | 0.90 | TACR2 (0.44) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | claimed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | claimed |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | claimed |
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| WO-2007037743-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | NISCH, BDKRB2, VIP | TACR2 8/4885TACR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.